303-A College Road East,
Princeton, New Jersey 08540
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset’s primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Pharmasset’s research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication.
Pharmasset was acquired by Gilead Sciences on January 17, 2012.
Join Mergr to view all 119 acquisitions of life science companies in 2012, including 19 acquisitions by private equity firms, and 100 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 18 in number of deals in 2012. The largest life science acquisition in 2012 was Pharmasset - which was acquired by Gilead Sciences for $11.0B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Pharmasset.
No obligation. Cancel anytime.